scholarly journals HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer

2021 ◽  
Author(s):  
Han Zhang ◽  
Jinlu Wang ◽  
Jingtong Li ◽  
Zhou Xiaoping ◽  
Lei Yin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tamoxifen Resistance ◽  
Key Factor

scholarly journals CD63 + Cancer‐Associated Fibroblasts Confer Tamoxifen Resistance to Breast Cancer Cells through Exosomal miR‐22

2020 ◽  
Vol 7 (21) ◽  
pp. 2002518
Author(s):  
Yuan Gao ◽  
Xiaoju Li ◽  
Cheng Zeng ◽  
Chenlin Liu ◽  
Qiang Hao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Tamoxifen Resistance ◽  
Cancer Associated Fibroblasts

scholarly journals Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance

2017 ◽  
Vol 24 (10) ◽  
pp. R349-R366 ◽  
Author(s):  
Catherine Zabkiewicz ◽  
Jeyna Resaul ◽  
Rachel Hargest ◽  
Wen Guo Jiang ◽  
Lin Ye
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Bone Morphogenetic Proteins ◽  
Therapeutic Potential ◽  
Current Knowledge ◽  
Breast Tumour ◽  
Cellular Functions ◽  
Foetal Development ◽  
Key Factor ◽  
The Right

Bone morphogenetic proteins (BMPs) belong to the TGF-β super family, and are essential for the regulation of foetal development, tissue differentiation and homeostasis and a multitude of cellular functions. Naturally, this has led to the exploration of aberrance in this highly regulated system as a key factor in tumourigenesis. Originally identified for their role in osteogenesis and bone turnover, attention has been turned to the potential role of BMPs in tumour metastases to, and progression within, the bone niche. This is particularly pertinent to breast cancer, which commonly metastasises to bone, and in which studies have revealed aberrations of both BMP expression and signalling, which correlate clinically with breast cancer progression. Ultimately a BMP profile could provide new prognostic disease markers. As the evidence suggests a role for BMPs in regulating breast tumour cellular function, in particular interactions with tumour stroma and the bone metastatic microenvironment, there may be novel therapeutic potential in targeting BMP signalling in breast cancer. This review provides an update on the current knowledge of BMP abnormalities and their implication in the development and progression of breast cancer, particularly in the disease-specific bone metastasis.

scholarly journals From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3688
Author(s):  
Jéssica Fernanda Barazetti ◽  
Tayana Shultz Jucoski ◽  
Tamyres Mingorance Carvalho ◽  
Rafaela Nasser Veiga ◽  
Ana Flávia Kohler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Estrogen Receptor Alpha ◽  
Expression Patterns ◽  
Tamoxifen Resistance ◽  
Hormone Receptor Positive ◽  
Current State ◽  
Main Driver ◽  
Underlying Mechanisms ◽  
Multiple Signaling

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer mortality among women. Two thirds of patients are classified as hormone receptor positive, based on expression of estrogen receptor alpha (ERα), the main driver of breast cancer cell proliferation, and/or progesterone receptor, which is regulated by ERα. Despite presenting the best prognosis, these tumors can recur when patients acquire resistance to treatment by aromatase inhibitors or antiestrogen such as tamoxifen (Tam). The mechanisms that are involved in Tam resistance are complex and involve multiple signaling pathways. Recently, roles for microRNAs and lncRNAs in controlling ER expression and/or tamoxifen action have been described, but the underlying mechanisms are still little explored. In this review, we will discuss the current state of knowledge on the roles of microRNAs and lncRNAs in the main mechanisms of tamoxifen resistance in hormone receptor positive breast cancer. In the future, this knowledge can be used to identify patients at a greater risk of relapse due to the expression patterns of ncRNAs that impact response to Tam, in order to guide their treatment more efficiently and possibly to design therapeutic strategies to bypass mechanisms of resistance.

scholarly journals Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer

Oncogene ◽  
2007 ◽  
Vol 26 (49) ◽  
pp. 6997-7005 ◽  
Author(s):  
J Bostner ◽  
M Ahnström Waltersson ◽  
T Fornander ◽  
L Skoog ◽  
B Nordenskjöld ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tamoxifen Resistance ◽  
Postmenopausal Breast Cancer ◽  
Predictors Of Recurrence

scholarly journals G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer

2011 ◽  
Vol 128 (2) ◽  
pp. 457-466 ◽  
Author(s):  
Atanas Ignatov ◽  
Tanja Ignatov ◽  
Christine Weißenborn ◽  
Holm Eggemann ◽  
Joachim Bischoff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
G Protein ◽  
Tamoxifen Resistance ◽  
G Protein Coupled

scholarly journals A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer

2014 ◽  
Vol 50 (16) ◽  
pp. 2866-2876 ◽  
Author(s):  
Ping Fan ◽  
Fadeke A. Agboke ◽  
Heather E. Cunliffe ◽  
Pilar Ramos ◽  
V. Craig Jordan
Keyword(s):  
Breast Cancer ◽  
Molecular Model ◽  
Tamoxifen Resistance

Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells

2009 ◽  
Vol 121 (3) ◽  
pp. 539-553 ◽  
Author(s):  
Shih-Hsin Tu ◽  
Chih-Chiang Chang ◽  
Ching-Shyang Chen ◽  
Ka-Wai Tam ◽  
Ying-Jan Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Tamoxifen Resistance ◽  
Human Breast Cancer Cells ◽  
Human Breast
Sign in / Sign up

Export Citation Format

Share Document